SCREENING SYSTEM FOR ANTIAPOPTOSIS THERAPEUTICS

抗凋亡治疗的筛选系统

• 批准号: 2038851
• 负责人: KATHERINE A WOOD
• 金额: $ 10万
• 依托单位: TREVIGEN, INC.
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-03-01 至 1998-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2038851
• 关键词: apoptosis; biotin; colorimetry; drug screening /evaluation; gene targeting; method development; protein purification; recombinant proteins; synthetic protein

The objective is to provide an assay for the screening of compounds that prevent apoptotic cell death. The product and method developed would be used by pharmaceutical companies for use in screening of their compounds to identify drugs for use in treatments for Parkinson's disease and other neurodegenerative disorders. Homodimer and heterodimer formation between members of the Bc1-2 family of proteins promote or prevent cell death. The specific aim is to produce a non-toxic assay in which disruption of dimer formation between the Bc1-2 family members is quantitated employing the innovative use of interactions between recombinant proteins. Drugs that block dimer formation are good candidates for modulation of apoptosis. The goal of Phase I is to develop the assay using Bax homodimer formation and to determine the optimal conditions for the assay under controlled conditions prior to a pilot testing of candidate drugs. During Phase II, the assay will be adapted for high throughput in robotic automatic screening systems and the system will be expanded to include the other Bc1-2 family members.

目的是提供一种筛选化合物的测定方法 的 防止细胞凋亡。 开发的产品和方法 将是 制药公司用于筛选 化合物 以确定用于治疗帕金森病的药物， 其他 神经退行性疾病 同二聚体和异二聚体形成 之间 Bc1 - 2蛋白家族的成员促进或阻止细胞凋亡， 死亡 具体目标是产生无毒测定，其中 破坏 定量Bc1 - 2家族成员之间的二聚体形成 采用 重组蛋白质之间相互作用的创新应用。 药物 嵌段二聚体形成是调节 凋亡 第一阶段的目标是开发使用Bax的检测方法 同二聚体的形成并确定最佳条件 测定 在对候选人进行试点测试之前， 毒品 在第二阶段，该测定法将适用于高通量， 机器人 自动筛选系统，该系统将扩大到 包括 Bc1 - 2家族成员